MarketPulse

immuno-pharma

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

AIM ImmunoTech Closes $1.8M Rights Offering to Fund Pancreatic Cancer Drug

AIM ImmunoTech closes $1.8M rights offering to advance Ampligen immunotherapy development for late-stage pancreatic cancer treatment.
AIMclinical trialswarrants
BenzingaBenzinga··Globe Newswire

AIM ImmunoTech Raises $1.8M Through Rights Offering as Biotech Seeks Capital

AIM ImmunoTech raises $1.8M through rights offering expiring March 3, 2026, providing working capital for ongoing immunotherapy operations.
AIMwarrantscapital raise